PODD

Neutral

Truist cuts Insulet stock price target to $219 on valuation

Truist Securities has lowered its price target for Insulet Corporation (NASDAQ:PODD) to $219 from $250, while maintaining a Buy rating. The valuation ...

Investing.com 11 mins ago 0

Neutral

Does Insulet’s (PODD) Omnipod 6 Data Reframe Its Type 2 Diabetes Automation Ambitions?

Insulet recently presented new clinical data on its Omnipod 6 and fully closed-loop system for type 2 diabetes, showing improved glucose control and p...

Simply Wall Street 23 hours ago 0

Bearish

Insulet recalls various Omnipod Pods due to potential insulin under-delivery

Insulet is recalling approximately 7 million Omnipod Pods globally due to a manufacturing defect that can cause insufficient insulin delivery, potenti...

Class Action Lawsuits Yesterday 0

Bullish

Insulet Data Supports Omnipod 6, Fully-Closed Loop AID Systems

Insulet released new clinical data supporting its Omnipod 6 and future fully closed-loop (FCL) automated insulin delivery (AID) systems. The STRIVE tr...

Medical Product Outsourcing 3 days ago 0

Neutral

ETFs Investing in Insulet Corporation Stocks

This article lists various Exchange Traded Funds (ETFs) that hold stocks of Insulet Corporation (GOV). It provides a detailed table including fund nam...

TradingView 5 days ago 0

Bullish

Insulet Reveals New Data Supporting Breakthrough Omnipod® 6 and Fully Closed-Loop AID Systems Designed to Improve Outcomes, Reduce Effort, and Unlock Barriers to Care

Insulet Corporation announced new clinical results for its Omnipod® 6 and fully closed-loop (FCL) system for type 2 diabetes, presented at the America...

Business Wire 5 days ago 0

Bullish

Insulin pump trials: Omnipod 6 lifts time in range with fewer boluses

Insulet Corporation announced new clinical data from the STRIVE pivotal trial and EVOLUTION 3 feasibility study, demonstrating significant improvement...

Stock Titan 5 days ago 0

Neutral

PODD Stock Balances Device Setback With Omnipod Upgrade Momentum

Insulet Corporation (PODD) stock is showing an uptrend despite a recent voluntary global medical device correction affecting millions of pods due to a...

StocksToTrade 5 days ago 0

Neutral

Independent Chair of Insulet Picks Up 66% More Stock

Insulet's Independent Chair, Elizabeth Weatherman, recently purchased US$497k worth of company stock at US$144 per share, increasing her holding by 66...

Simply Wall Street 6 days ago 0

Bullish

Insulet to Spotlight New Data and Innovations Demonstrating How Omnipod® Simplifies Diabetes Management and Delivers Strong Clinical Outcomes at the American Diabetes Association 86th Scientific Sessions

Insulet Corporation announced its plans for the American Diabetes Association's 86th Scientific Sessions, highlighting new data and innovations for it...

BioSpace 1 week ago 0

Bullish

Insulet to Spotlight New Data and Innovations Demonstrating How Omnipod® Simplifies Diabetes Management and Delivers Strong Clinical Outcomes at the American Diabetes Association 86th Scientific Sessions

Insulet Corporation announced its plans for the American Diabetes Association's 86th Scientific Sessions, where it will showcase new data and innovati...

Business Wire 1 week ago 0

Bullish

Insulet's Omnipod 5 Update: A Masterclass in Personalized Health Tech

Insulet Corporation has launched significant enhancements for its Omnipod 5 Automated Insulin Delivery (AID) System, including a new 100 mg/dL target ...

BriefGlance 1 week ago 0

Bullish

Insulet Rolls Out New Omnipod 5 Algorithm, Compatibility with Abbott’s FreeStyle Libre 3 Plus

Insulet has launched new algorithm enhancements for its Omnipod 5 automated insulin delivery system, including a 100 mg/dL Target Glucose option for g...

Medical Product Outsourcing 1 week ago 0

Bullish

New Omnipod 5 update lets U.S. users aim for 100 mg/dL, use Libre 3 Plus

Insulet Corporation has announced the U.S. rollout of enhanced Omnipod 5 algorithm updates, allowing users to aim for a 100 mg/dL target glucose and i...

Stock Titan 1 week ago 0

Bullish

5 Algorithm and Expands Compatibility with Abbott’s FreeStyle Libre 3 Plus Sensor

Insulet Corporation announced the U.S. rollout of an enhanced Omnipod 5 Automated Insulin Delivery (AID) System algorithm and expanded compatibility w...

Business Wire 1 week ago 0

Neutral

Court overturns Insulet’s $59M trade secret verdict against EOFlow

A U.S. appeals court has overturned a $59.4 million trade secret award to Insulet against rival insulin pump company EOFlow. The court ruled that Insu...

Yahoo Finance 1 week ago 0

Bearish

TD Cowen Adjusts Insulet Price Target to $294 From $379, Maintains Hold Rating

TD Cowen has revised its price target for Insulet (NASDAQ: PODD) from $379 to $294, while keeping a "Hold" rating on the stock. This adjustment comes ...

www.marketscreener.com 1 week ago 0

Bearish

US appeals court overturns Insulet's $59 million (not $452 mln) insulin-pump trade secret verdict against rival Eoflow | MarketScreener

A US appeals court has overturned a $59 million trade secret verdict that Insulet Corporation had won against its rival Eoflow regarding insulin-pump ...

marketscreener.com 2 weeks ago 0

Bearish

Insulet’s $59 Million Trade Secrets Award Voided by Court

A federal court has voided a $59.4 million trade secrets award that Insulet Corp. initially won against EOFlow Co. Ltd. The court ruled that Insulet f...

Bloomberg Law News 2 weeks ago 0

Neutral

Insulet Corporation stock hits 52-week low at $143.95 By Investing.com

Insulet Corporation's stock has dropped to a 52-week low of $143.95, reflecting a challenging year with a 52.46% decline. Despite this, InvestingPro d...

Investing.com Australia 2 weeks ago 0